Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 2
1972 1
1973 6
1974 10
1975 6
1976 2
1977 9
1978 8
1979 14
1980 7
1981 8
1982 13
1983 7
1984 23
1985 17
1986 16
1987 21
1988 18
1989 22
1990 21
1991 31
1992 22
1993 31
1994 28
1995 21
1996 27
1997 29
1998 16
1999 15
2000 30
2001 17
2002 26
2003 22
2004 30
2005 30
2006 27
2007 23
2008 31
2009 29
2010 45
2011 53
2012 43
2013 54
2014 66
2015 77
2016 84
2017 87
2018 78
2019 86
2020 107
2021 113
2022 83
2023 94
2024 37

Text availability

Article attribute

Article type

Publication date

Search Results

1,660 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.
Labori KJ, Bratlie SO, Andersson B, Angelsen JH, Biörserud C, Björnsson B, Bringeland EA, Elander N, Garresori H, Grønbech JE, Haux J, Hemmingsson O, Liljefors MG, Myklebust TÅ, Nymo LS, Peltola K, Pfeiffer P, Sallinen V, Sandström P, Sparrelid E, Stenvold H, Søreide K, Tingstedt B, Verbeke C, Öhlund D, Klint L, Dueland S, Lassen K; Nordic Pancreatic Cancer Trial-1 study group. Labori KJ, et al. Among authors: andersson b. Lancet Gastroenterol Hepatol. 2024 Mar;9(3):205-217. doi: 10.1016/S2468-1253(23)00405-3. Epub 2024 Jan 15. Lancet Gastroenterol Hepatol. 2024. PMID: 38237621 Clinical Trial.
Patients in the neoadjuvant FOLFIRINOX group received four neoadjuvant cycles of FOLFIRINOX (oxaliplatin 85 mg/m(2), irinotecan 180 mg/m(2), leucovorin 400 mg/m(2), and fluorouracil 400 mg/m(2) bolus then 2400 mg/m(2) over 46 h on day 1 of each …
Patients in the neoadjuvant FOLFIRINOX group received four neoadjuvant cycles of FOLFIRINOX (oxaliplatin 85 mg/m(2), irinotecan 180 m …
Human genome meeting 2016 : Houston, TX, USA. 28 February - 2 March 2016.
Srivastava AK, Wang Y, Huang R, Skinner C, Thompson T, Pollard L, Wood T, Luo F, Stevenson R, Polimanti R, Gelernter J, Lin X, Lim IY, Wu Y, Teh AL, Chen L, Aris IM, Soh SE, Tint MT, MacIsaac JL, Yap F, Kwek K, Saw SM, Kobor MS, Meaney MJ, Godfrey KM, Chong YS, Holbrook JD, Lee YS, Gluckman PD, Karnani N; GUSTO study group; Kapoor A, Lee D, Chakravarti A, Maercker C, Graf F, Boutros M, Stamoulis G, Santoni F, Makrythanasis P, Letourneau A, Guipponi M, Panousis N, Garieri M, Ribaux P, Falconnet E, Borel C, Antonarakis SE, Kumar S, Curran J, Blangero J, Chatterjee S, Kapoor A, Akiyama J, Auer D, Berrios C, Pennacchio L, Chakravarti A, Donti TR, Cappuccio G, Miller M, Atwal P, Kennedy A, Cardon A, Bacino C, Emrick L, Hertecant J, Baumer F, Porter B, Bainbridge M, Bonnen P, Graham B, Sutton R, Sun Q, Elsea S, Hu Z, Wang P, Zhu Y, Zhao J, Xiong M, Bennett DA, Hidalgo-Miranda A, Romero-Cordoba S, Rodriguez-Cuevas S, Rebollar-Vega R, Tagliabue E, Iorio M, D’Ippolito E, Baroni S, Kaczkowski B, Tanaka Y, Kawaji H, Sandelin A, Andersson R, Itoh M, Lassmann T; The FANTOM5 Consortium; Hayashizaki Y, Carninci P, Forrest ARR, Semple CA, Rosenthal EA, Shirts B, Amendola L, Gallego C, Hori… See abstract for full author list ➔ Srivastava AK, et al. Among authors: andersson r. Hum Genomics. 2016 May 26;10 Suppl 1(Suppl 1):12. doi: 10.1186/s40246-016-0063-5. Hum Genomics. 2016. PMID: 27294413 Free PMC article.
M. Saw, M. S. Kobor, M. J. Meaney, K. M. Godfrey, Y. S. Chong, J. ...M. Edrees, M. Athar, F. A. Al-Allaf, M. M. Taher, W. Khan, A. Bouazzaoui, N. ...
M. Saw, M. S. Kobor, M. J. Meaney, K. M. Godfrey, Y. S. Chong, J. ...M. Edrees, M. Athar, F. A. Al …
Mucosal immunity.
Hanson LA, Ahlstedt S, Andersson B, Carlsson B, Cole MF, Cruz JR, Dahlgren U, Ericsson TH, Jalil F, Khan SR, Mellander L, Schneerson R, Edén CS, Söderström T, Wadsworth C. Hanson LA, et al. Among authors: andersson b. Ann N Y Acad Sci. 1983 Jun 30;409:1-21. doi: 10.1111/j.1749-6632.1983.tb26855.x. Ann N Y Acad Sci. 1983. PMID: 6191608 Review.
Thrombectomy versus Medical Management for Isolated Anterior Cerebral Artery Stroke: An International Multicenter Registry Study.
Meyer L, Stracke P, Broocks G, Elsharkawy M, Sporns P, Piechowiak EI, Kaesmacher J, Maegerlein C, Hernandez Petzsche MR, Zimmermann H, Naziri W, Abdullayev N, Kabbasch C, Diamandis E, Thormann M, Maus V, Fischer S, Möhlenbruch M, Weyland CS, Ernst M, Jamous A, Meila D, Miszczuk M, Siebert E, Lowens S, Krause LU, Yeo L, Tan B, Gopinathan A, Arenillas-Lara JF, Navia P, Raz E, Shapiro M, Arnberg F, Zeleňák K, Martínez-Galdámez M, Alexandrou M, Kastrup A, Papanagiotou P, Kemmling A, Dorn F, Psychogios M, Andersson T, Chapot R, Fiehler J, Hanning U; TOPMOST Study Group. Meyer L, et al. Among authors: andersson t. Radiology. 2023 Apr;307(2):e220229. doi: 10.1148/radiol.220229. Epub 2023 Feb 14. Radiology. 2023. PMID: 36786705
Muscarinic acetylcholine receptors in the urinary tract.
Andersson KE. Andersson KE. Handb Exp Pharmacol. 2011;(202):319-44. doi: 10.1007/978-3-642-16499-6_16. Handb Exp Pharmacol. 2011. PMID: 21290234 Review.
Preferentially, the inhibitory muscarinic M(2) and M(4) receptors couple to G(i/o), whereas the excitatory muscarinic M(1), M(3), and M(5) receptors preferentially couple to G(q/11). In general, muscarinic M(1), M(3), and M( …
Preferentially, the inhibitory muscarinic M(2) and M(4) receptors couple to G(i/o), whereas the excitatory muscarinic M …
Adjunct immunotherapies for tuberculosis.
Uhlin M, Andersson J, Zumla A, Maeurer M. Uhlin M, et al. Among authors: andersson j. J Infect Dis. 2012 May 15;205 Suppl 2:S325-34. doi: 10.1093/infdis/jis197. Epub 2012 Mar 29. J Infect Dis. 2012. PMID: 22457298 Review.
Augmentation or dampening of proinflammatory responses can be of value in the treatment of individuals who have nonproductive M. tuberculosis infection with inflammation-induced tissue damage. The use of immunotherapy with interleukin 2, interferon gamma, and interleukin 7 …
Augmentation or dampening of proinflammatory responses can be of value in the treatment of individuals who have nonproductive M. tube …
Inflammation and tuberculosis: host-directed therapies.
Zumla A, Rao M, Parida SK, Keshavjee S, Cassell G, Wallis R, Axelsson-Robertsson R, Doherty M, Andersson J, Maeurer M. Zumla A, et al. Among authors: andersson j. J Intern Med. 2015 Apr;277(4):373-87. doi: 10.1111/joim.12256. Epub 2014 May 19. J Intern Med. 2015. PMID: 24717092 Free article. Review.
Multidrug-resistant (MDR) TB is caused by strains of Mycobacterium tuberculosis (M. tb) resistant to isoniazid and rifampin, the backbone of first-line antitubercular treatment. ...'Target-organ-saving' strategies may be warranted to prevent damage to infected tissues and …
Multidrug-resistant (MDR) TB is caused by strains of Mycobacterium tuberculosis (M. tb) resistant to isoniazid and rifampin, the back …
Challenges of acute endovascular stroke trials.
Goyal M, Almekhlafi M, Menon B, Hill M, Fargen K, Parsons M, Bang OY, Siddiqui A, Andersson T, Mendes V, Davalos A, Turk A, Mocco J, Campbell B, Nogueira R, Gupta R, Murphy S, Jovin T, Khatri P, Miao Z, Demchuk A, Broderick JP, Saver J. Goyal M, et al. Among authors: andersson t. Stroke. 2014 Oct;45(10):3116-22. doi: 10.1161/STROKEAHA.114.006288. Epub 2014 Aug 28. Stroke. 2014. PMID: 25169945 No abstract available.
Totally drug-resistant tuberculosis and adjunct therapies.
Parida SK, Axelsson-Robertson R, Rao MV, Singh N, Master I, Lutckii A, Keshavjee S, Andersson J, Zumla A, Maeurer M. Parida SK, et al. Among authors: andersson j. J Intern Med. 2015 Apr;277(4):388-405. doi: 10.1111/joim.12264. Epub 2014 Jun 18. J Intern Med. 2015. PMID: 24809736 Free article. Review.
Although there is no consensus on terminology, it is most commonly described as 'resistance to all first- and second-line drugs used to treat TB'. Mycobacterium tuberculosis (M.tb) acquires drug resistance mutations in a sequential fashion under suboptimal drug pressure du …
Although there is no consensus on terminology, it is most commonly described as 'resistance to all first- and second-line drugs used to trea …
Cognitive Effects of Perioperative Pregabalin: Reply.
Myhre M, Jacobsen HB, Andersson S, Stubhaug A. Myhre M, et al. Among authors: andersson s. Anesthesiology. 2019 Sep;131(3):753-754. doi: 10.1097/ALN.0000000000002872. Anesthesiology. 2019. PMID: 31299657 Free article. No abstract available.
1,660 results